sur Evotec AG (NASDAQ:EVTCY)
Evotec SE Outlines New Strategy with 2025 Guidance Following Strong Q4 2024 Performance
Evotec SE announced a strategic pivot towards sustainable, profitable growth. The company aims to leverage its technological and scientific leadership, particularly in high-growth sectors. Despite a challenging market, Evotec reported strong Q4 2024 results, meeting full-year guidance with improved liquidity.
The strategy emphasizes two main pillars: Drug Discovery & Pre-clinical Development, and Just – Evotec Biologics. Evotec plans to streamline operations, focusing on high-value services, and expects annual recurring savings of €40 million. The company forecasts 2025 revenues to grow 5-10% and anticipates a compound annual growth rate of 8-12% by 2028, alongside an EBITDA margin above 20%.
Evotec's Q4 2024 revenues rose by 10%, driven by significant growth in the Just – Evotec Biologics segment. The company strengthens its position through partnerships with industry giants like Bristol Myers Squibb and Pfizer, aiming for stable growth in 2025.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Evotec AG